Induction of apoptosis by beta-diketones in human tumor cells
Kensuke Nakano1, Tohru Nakayachi, Eiji Yasumoto
1Department of Dental Pharmacology, Meikai University School of Dentistry, Sakado, Saitama, Japan.
Abstract:
A variety of beta-diketones were evaluated for their cytotoxic profiles against oral human normal and tumor cells. Among 22 compounds (BD1-22) tested, the cytotoxicity of 3-formylchromone (BD17) (CC50=7.8 microg/mL) against human oral squamous cell carcinoma (HSC-2) cells was higher than that of curcumin (CC50=23.6 microg/mL). Tumor cell-specific cytotoxicity was also detected in BD17 which exhibited little cytotoxic activity against a normal human cell, gingival fibroblast (HGF). (-)-3- (BD13) (CC50=21.7 microg/mL) and (+)-3-(Trifluoroacetyl)camphor (BD12) (CC50=29.7 microg/mL) are enantiomers and showed cytotoxicity comparable to curcumin and dibenzoylmethane (BD2) (CC50=22.5 microg/mL). BD13 did not induce DNA fragmentation in HL-60 cells nor activate caspase 3, 8 and 9 in both HL-60 and HSC-2 cells, regardless of the presence or absence of FeCl3. On the other hand, BD17 was found to induce apoptosis in HSC-2 and HL-60 cells, as judged by internucleosomal DNA fragmentation, caspase 3, 8 and 9 activation and dysfunction of mitochondrial membrane potential. The cytotoxic activity of BD13, BD17 and curcumin was significantly reduced by chelation with FeCl3. The tumor-specific cytotoxicity and apoptosis-inducing activity of BD17 against human tumor cells undoubtedly warrant further studies of its efficacy as a cancer chemotherapeutic agent.
Insights
Researchers screened beta-diketones for cancer cell toxicity. 3-formylchromone (BD17) showed potent, tumor-specific cytotoxicity against oral cancer cells, inducing apoptosis and warranting further study as a potential cancer therapeutic.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Cancer Biology
Background:
- Beta-diketones are a class of organic compounds with diverse biological activities.
- Oral cancer remains a significant global health challenge, necessitating novel therapeutic strategies.
- Curcumin and dibenzoylmethane are known for their anti-cancer properties.
Purpose of the Study:
- To evaluate the cytotoxic effects of various beta-diketones against oral human normal and tumor cell lines.
- To identify novel beta-diketone compounds with potent and selective anti-cancer activity.
- To investigate the mechanisms of action for promising compounds, including apoptosis induction.
Main Methods:
- Cytotoxicity assays were performed on human oral squamous cell carcinoma (HSC-2) and normal gingival fibroblast (HGF) cells.
- Twenty-two beta-diketone compounds (BD1-22) were screened.
- Apoptosis induction was assessed by DNA fragmentation, caspase activation (caspase 3, 8, 9), and mitochondrial membrane potential changes.
Main Results:
- 3-formylchromone (BD17) exhibited significant cytotoxicity against HSC-2 cells (CC50=7.8 microg/mL), outperforming curcumin (CC50=23.6 microg/mL).
- BD17 demonstrated tumor-specific cytotoxicity, with minimal impact on normal HGF cells.
- BD17 induced apoptosis in HSC-2 and HL-60 cells via DNA fragmentation, caspase activation, and mitochondrial dysfunction.
- Enantiomers (-)-3- (BD13) and (+)-3-(Trifluoroacetyl)camphor (BD12) showed cytotoxicity comparable to curcumin.
Conclusions:
- 3-formylchromone (BD17) possesses potent and tumor-specific cytotoxic activity against oral cancer cells.
- BD17 effectively induces apoptosis, suggesting its potential as a novel cancer chemotherapeutic agent.
- Further preclinical studies are warranted to explore the therapeutic efficacy of BD17.
Related Concept Videos
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
Apoptosis
Inhibition of Cdk Activity
Cellular Injury V: Apoptosis and Autophagy

